ARTIMES Neural Network Successfully Completes Clinical Trials for Evaluating Chemotherapy Efficacy in Mesothelioma

The ARTIMES AI system has passed clinical trials and now assists oncologists in combating malignant pleural mesothelioma. The leading medical journal *The Lancet Oncology* reports that this innovative algorithm evaluates the treatment efficacy for this aggressive cancer type with millimeter precision. The new technology completely removes subjective bias from the visual analysis of medical scans. Doctors now have a reliable tool to accurately determine the tumor’s response to chemotherapy and adjust the treatment course in real time.

Asbestos exposure is the leading cause of mesothelioma in patients. Malignant cells spread across the lung tissue like a formless crust or web, unlike tumors that form dense, spherical masses. This specific growth pattern makes standard measurements on CT and MRI scans unreliable, as radiologists struggle to determine if the affected area has actually shrunk. The ARTIMES algorithm solves this issue through automated volumetric analysis.

The neural network creates a 3D overlay of fresh lung scans onto the patient’s previous images. The system mathematically calculates even the most microscopic volume changes in the cancerous tissue. If the algorithm detects a lack of response to the current therapy, the oncologist gains an objective data-driven reason to halt the drug immediately.

This rapid decision protects the weakened patient from unnecessary toxic side effects and allows for a prompt transition to experimental immunotherapy or other personalized treatment protocols.